How the EU Medical Device Regulation will affect the GCC

Due to the global Covid-19 pandemic, the EU has postponed the introduction of the new EU Medical Device Regulation (MDR) (2017/745) to 26 May 2021 from the same date that was proposed this year. But it is time to roll up your sleeves and race against time because the new regulation is four times longer than its predecessor, the Medical Device Directive (MDD) and contains five more annexes.

Within a year, 1000s of medical devices (MDs) will move to a higher risk class and will have to be re-assessed by a notified body before they receive a CE mark and re-enter the European market.

Hence, it is crucial that all GCC distributors who import registered MDs from the EU immediately get in touch with the manufacturers from the country of origin and clarify the validity of their CE mark and ISO certificates. It is very important to understand the timeframe for your business to remain in the safe zone before your current import changes categories.

Besides, most manufacturers will also have to update their technical documentation, quality assurance and risk management to name a few EU requirements. Let me give some clarity about key changes

  • The definition of MDs will be broadened to include non-medical products for cleaning and sterilization of devices and cosmetic devices such as contact lenses, liposuction equipment and epilation lasers.
  • It will be mandatory for a notified body to issue the certificate of conformity (CoC) for integral MDs such as transdermal patches, pre-filled syringes, inhalers. Or co-packaged devices such as a reusable pen that contains a disposable insulin cartridge.
  • GCC distributors must also take note that the MDR raises the compliance requirement for implantable devices and several other devices, which will be moved into a higher risk category with very stringent requirements at every stage.
  • Manufacturers can self-certify only Class I devices
  • We will see the implementation of a Unique Device Identification (UDI) to help track devices throughout the supply chain.
  • Post-market surveillance will become a norm and manufacturers will need to provide in-depth clinical data to prove safety and performance claims, including tighter equivalency standards.
  • EU manufacturers must report all incidents, injuries and deaths into a centralized EU portal, which will give patients complete access to all safety-related information.
  • The In Vitro Diagnostic Medical Device Regulation (IVDR) (2017/746) will be effective from 26 May 2022.
  • Around 90 per cent of IVDs will be recategorized into four risk classes under a rigorous hazard-based system and will require notified body reviews; up from the current 10 per cent.

Severe delays

This Bodes well for patients. But this will delay the marketing and distribution of significant medical devices and, in turn, affect patient treatment, tracking and outcome. A market survey by Medtech Intelligence revealed that over half of the companies estimate that they will need to earmark more than 10% of their revenue to comply with the new regulations. It also predicts severe delays in re-authorization of existing devices and authorization of new products due to the declining number of notified bodies across the EU who are accredited to issue the CoCs.

With the new regulations, so far only 12 notified bodies fall in the list approved by the European Commission – a far cry from their end-2019 forecast of 20 bodies making it to the list. Why? Several of the 58 approved notified bodies have announced that they would not seek designation under the MDR due to the stringent rules and increased number of affected medical devices.

As a result, European start-ups, small- and medium-sized companies that lack the active infrastructure to meet the MDR may move their business to other countries such as US or China. They may also shift to other regulatory authorities and shift operations too. For example, certain French companies are taking their business to Morocco.

GCC alert

Hence, all GCC distributors must check all registration certificates and talk to the EU manufacturers to first find out if they will shift the country of origin on the registered names. If the devices don’t get certified in the EU, then the various health ministries in the GCC countries will not permit them to be registered here either.

Also, the re-certification of existing devices from the manufacturer’s end means a delay from the GCC authorities to authorize new products – the current process takes between three to nine months.

I would also like to recommend that it is a good time for the regulatory authorities in the Gulf to give us clear guidelines on

a) What happens to registered MD whose classifications will change next year?

b) Will we see a variation process or will the registration move to new product applications?

c) What will be the new timelines for the business owners and distributors to implement the changes?

Above all, we hope to also get clarity on the grace period for the business owner and distributors. These are just some of the questions that the entire industry will seek more guidance in the long run.

Published by:

Mona Al Moussli

Co-founder PRA | Experienced pharma reg affairs consultant | MSc KREMS, Vienna | Middle-East MOH network

Published on: July 2, 2020

Share:

Leave a Reply

Your email address will not be published. Required fields are marked *

Let's talk

If you want to get a free consultation without any obligations, fill in the form below and we'll get in touch with you.